PDF herunterladen
Thromb Haemost 2002; 88(01): 26-31
DOI: 10.1055/s-0037-1613148
Review Article
Schattauer GmbH

Association of γA/γ’ Fibrinogen Levels and Coronary Artery Disease

Rehana S. Lovely
1   Department of Pathology, Oregon Health & Science University, Portland, OR
,
Lisa A. Falls
3   Center for Hemostasis and Thrombosis Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
,
Hamid A. Al-Mondhiry
4   Department of Medicine, The Pennsylvania State University College of Medicine, Hershey, PA
,
Charles E. Chambers
4   Department of Medicine, The Pennsylvania State University College of Medicine, Hershey, PA
,
Gary J. Sexton
2   Clinical Research Center, Oregon Health & Science University, Portland, OR
,
Hanyu Ni
5   Division of Health Interview Statistics, National Center for Health Statistics, Hyattsville, MD, USA
,
David H. Farrell
1   Department of Pathology, Oregon Health & Science University, Portland, OR
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 27. Dezember 2001

Accepted 27. Februar 2002

Publikationsdatum:
09. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

γA/γ’ fibrinogen is a fibrinogen isoform that constitutes about 15% of total plasma fibrinogen. This isoform contains an additional binding site for zymogen factor XIII and for active thrombin, and forms fibrin clots that are resistant to fibrinolysis in vitro. Little is known about the variability of γA/γ’ fibrinogen levels in human populations, whereas total fibrinogen levels are known to increase with age and are higher in women than in men. In this report, evidence is presented that, in contrast to total fibrinogen levels, γA/γ’ fibrinogen levels showed no significant association with age or gender in a population of normal blood donors. A study of γA/γ’ fibrinogen levels in patients undergoing coronary angiography also showed that γA/γ’ fibrinogen levels were higher on average in coronary artery disease patients than in patients without coronary artery disease, and that this association was independent of total fibrinogen levels.

Keywords

Age - coronary - epidemiology - fibrinogen - gender
 

  • References

  • 1 Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal γ chain variant (γ’). Proc Natl Acad Sci USA 1980; 77: 5069-73.
    CrossrefPubMedSuche in Google Scholar
  • 2 Francis CW, Marder VJ, Martin SE. Demonstration of a large molecular weight variant of the γ chain of normal human plasma fibrinogen. J Biol Chem 1980; 255: 5599-604.
    PubMedSuche in Google Scholar
  • 3 Francis CW, Kraus DH, Marder VJ. Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three γ-chain types with distinct molecular weights. Biochim Biophys Acta 1983; 744: 155-64.
    CrossrefPubMedSuche in Google Scholar
  • 4 Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of a human fibrinogen γ-chain variant (γ’). Biochemistry 1981; 20: 6146-9.
    CrossrefPubMedSuche in Google Scholar
  • 5 Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities: identification of γ chain variants. J Biol Chem 1972; 247: 5223-7.
    PubMedSuche in Google Scholar
  • 6 Chung DW, Davie EW. γ and γ’ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984; 23: 4232-6.
    CrossrefPubMedSuche in Google Scholar
  • 7 Fornace AJ, Cummings DE, Comeau CM, Kant JA, Crabtree GR. Structure of the human γ-fibrinogen gene: alternate mRNA splicing near the 3’ end of the gene produces γA and γB forms of γ-fibrinogen. J Biol Chem 1984; 259: 12826-30.
    PubMedSuche in Google Scholar
  • 8 Farrell DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen α and γ chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729-32.
    CrossrefPubMedSuche in Google Scholar
  • 9 Lawrence SO, Wright TW, Francis CW, Fay PJ, Haidaris PJ. Purification and functional characterization of homodimeric γB-γB fibrinogen from rat plasma. Blood 1993; 82: 2406-13.
    PubMedSuche in Google Scholar
  • 10 Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 1994; 269: 226-31.
    PubMedSuche in Google Scholar
  • 11 Crabtree GR, Kant JA. Organization of the rat γ-fibrinogen gene: alternative mRNA splice patterns produce the γA and γB (γ’) chains of fibrinogen. Cell 1982; 31: 159-66.
    CrossrefPubMedSuche in Google Scholar
  • 12 Haidaris PJ, Courtney MA. Tissue-specific and ubiquitous expression of fibrinogen γ chain mRNA. Blood Coagul Fibrinolysis 1990; 01: 433-7.
    CrossrefPubMedSuche in Google Scholar
  • 13 Farrell DH, Mulvihill ER, Huang S, Chung DW, Davie EW. Recombinant human fibrinogen and sulfation of the γ’ chain. Biochemistry 1991; 30: 9414-20.
    CrossrefPubMedSuche in Google Scholar
  • 14 Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing γ’ chains. Biochemistry 1996; 35: 10448-53.
    CrossrefPubMedSuche in Google Scholar
  • 15 Moaddel M, Farrell DH, Daugherty MA, Fried MG. Interactions of human fibrinogens with factor XIII: roles of calcium and the γ’ peptide. Biochemistry 2000; 39: 6698-705.
    CrossrefPubMedSuche in Google Scholar
  • 16 Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of thrombin binding sites on fibrin. J Biol Chem 1996; 271: 23121-5.
    CrossrefPubMedSuche in Google Scholar
  • 17 Meh D, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb Haemost 2001; 85: 470-4.
    Thieme ConnectPubMedSuche in Google Scholar
  • 18 Falls LA, Farrell DH. Resistance of γA/γ' fibrin clots to fibrinolysis. J Biol Chem 1997; 272: 14251-6.
    CrossrefPubMedSuche in Google Scholar
  • 19 Lorand L. Sol Sherry Lecture on Thrombosis: Research on Clot Stabilization Provides Clues for Improving Thrombolytic Therapies. Arterioscler Thromb Vasc Biol 2000; 20: 2-9.
    CrossrefPubMedSuche in Google Scholar
  • 20 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23.
    CrossrefPubMedSuche in Google Scholar
  • 21 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
    CrossrefPubMedSuche in Google Scholar
  • 22 Drouet L, Paolucci F, Pasqualini N, Laprade M, Ripoll L, Mazoyer E, Bal Cdit Sollier, Vanhove N. Plasma γA/γ' fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor?. Blood Coagul Fibrinolysis 1999; 10 (Suppl. 01) S35-S39.
    PubMedSuche in Google Scholar
  • 23 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
    CrossrefPubMedSuche in Google Scholar
  • 24 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thrompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 02: 533-7.
    PubMedSuche in Google Scholar
  • 25 Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 1183-6.
    CrossrefPubMedSuche in Google Scholar
  • 26 Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-44.
    CrossrefPubMedSuche in Google Scholar
  • 27 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
    CrossrefPubMedSuche in Google Scholar
  • 28 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 1102-8.
    CrossrefPubMedSuche in Google Scholar
  • 29 Grieninger G, Hertzberg KM, Pindyck J. Fibrinogen synthesis in serumfree hepatocyte cultures: stimulation by glucocorticoids. Proc Natl Acad Sci USA 1978; 75: 5506-10.
    CrossrefPubMedSuche in Google Scholar
  • 30 Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and nonsmokers. Thromb Haemost 1991; 65: 487-90.
    Thieme ConnectPubMedSuche in Google Scholar
  • 31 Fowkes FG, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GD. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-6.
    CrossrefPubMedSuche in Google Scholar
  • 32 Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann NY Acad Sci 2001; 936: 549-59.
    PubMedSuche in Google Scholar
  • 33 Folsom AR, Wu KK, Rasmussen M, Chambless LE, Aleksic N, Nieto FJ. Determinants of population changes in fibrinogen and factor VII over 6 years: the Atherosclerosis in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 2000; 20: 601-6.
    CrossrefPubMedSuche in Google Scholar
  • 34 Kannel WB, D'Agostino RB, Belanger AJ, Silbershatz H, Tofler GT. Long-term influence of fibrinogen on initial and recurrent cardiovascular events in men and women. N Engl J Med 1996; 78: 90-2.
    PubMedSuche in Google Scholar
  • 35 Folsom AR, Wu K, Sharrett A, Chambless L. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 1102-8.
    CrossrefPubMedSuche in Google Scholar
  • 36 Flaherty MJ, West S, Heimark RL, Fujikawa K, Tait JF. Placental anticoagulant protein-I: measurement in extracellular fluids and cells of the hemostatic system. J Lab Clin Med 1990; 115: 174-81.
    PubMedSuche in Google Scholar
  • 37 Lowe GDO, Rumley A. Fibrinogen and its degradation products as thrombotic risk factors. Ann NY Acad Sci 2001; 936: 560-5.
    PubMedSuche in Google Scholar
  • 38 Yu S, Sher B, Kudryk B, Redman CM. Fibrinogen precursors: order of assembly of fibrinogen chains. J Biol Chem 1984; 259: 10574-81.
    PubMedSuche in Google Scholar
  • 39 Moaddel M, Falls LA, Farrell DH. The role of γA/γ' fibrinogen in plasma factor XIII activation. J Biol Chem 2000; 275: 32135-40.
    CrossrefPubMedSuche in Google Scholar